Does baclofen suppository lower heart rate?

Does Baclofen Suppository Lower Heart Rate?

Baclofen does not directly lower heart rate through its pharmacologic mechanism, but it can cause bradycardia as a serious adverse effect, particularly during withdrawal or in predisposed patients with spinal cord injury. The drug's primary cardiovascular effects are related to its GABA-B agonist activity on the central nervous system rather than direct cardiac action.

Mechanism and Direct Cardiac Effects

• Baclofen works via gamma-aminobutyric acid (GABA) receptors as a centrally acting spasmolytic agent and does not have intrinsic bradycardic properties like beta-blockers or calcium channel blockers 1
• In patients receiving extended-release baclofen 20 mg twice daily, the drug does not directly induce bradycardia via cardiac pathways 2
• However, individuals who develop ventricular bigeminy or trigeminy may exhibit an apparent bradycardia and pulse deficit between apical and radial sites, reflecting effective bradycardia despite normal intrinsic rhythm 2

Paradoxical Bradycardia in Specific Populations

Patients with spinal cord injury above T6 are at highest risk for baclofen-induced bradycardia, particularly those with autonomic dysreflexia:

• In tetraplegic patients, even a single 5 mg therapeutic dose of oral baclofen can cause severe bradycardia (as low as 30 bpm), hypotension (60/30 mmHg), and cardiac conduction problems requiring pacemaker implantation 3
• A 50 μg intrathecal baclofen test bolus produced bradycardia (58 bpm) within 10 minutes in one brain injury patient, while a 20 μg bolus caused severe bradycardia (30 bpm) after 5 minutes in a spinal cord injury patient 4
• The observed bradycardia in autonomic dysreflexia is explained as a baroreceptor reflex response to high blood pressure rather than direct cardiac suppression 5

Life-Threatening Withdrawal Bradycardia

Abrupt baclofen discontinuation poses greater cardiac risk than the drug itself:

• Baclofen withdrawal can precipitate severe bradyarrhythmia and associated reduced cardiac output/arrest requiring inotropic and vasopressor support 6
• Withdrawal symptoms include tachycardia (not bradycardia initially), but severe bradyarrhythmia can develop 36 hours after cessation, requiring baclofen reintroduction for resolution 1, 6
• Intrathecal baclofen withdrawal is potentially life-threatening, with symptoms including high fever, altered mental status, rebound spasticity, muscle rigidity leading to rhabdomyolysis, multiorgan failure, and death 1, 2

Clinical Monitoring Recommendations

For patients initiating any form of baclofen therapy:

• Perform baseline heart rate and blood pressure assessment before starting treatment 2
• Conduct weekly heart rate checks (by pulse, event recorder, or office ECG) throughout the first month to detect early bradycardia 2
• Careful cardiological examination before intrathecal baclofen treatment and close monitoring during testing is advised, as cardiovascular dysfunction may be heralded by baclofen in predisposed patients 4

Critical Safety Caveat

Two patients who developed bradycardia after intrathecal baclofen test boluses (50 μg and 20 μg respectively) suffered fatal cardiac arrest one and two months later despite numerous unremarkable repeat cardiological examinations 4. This suggests baclofen may unmask underlying cardiovascular vulnerability even when standard cardiac workup appears normal.

Route-Specific Considerations

While your question asks specifically about suppositories, the available evidence addresses oral and intrathecal routes. The suppository formulation would be expected to have systemic absorption similar to oral administration, making the cardiovascular precautions equally applicable 1, 4, 3.